SCA
NVO

Snowden Capital Advisors’s Novo Nordisk NVO Stock Holding History

Snowden Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
41,480
+787
+2% +$33.8K 0.05% 360
2026
Q1 		$1.55M Sell
40,693
-19,862
-33% -$941K 0.04% 401
2025
Q4 		$3.08M Buy
60,555
+22,721
+60% +$1.16M 0.08% 245
2025
Q3 		$2.1M Buy
37,834
+2,605
+7% +$152K 0.06% 312
2025
Q2 		$2.43M Sell
35,229
-7,251
-17% -$493K 0.07% 265
2025
Q1 		$3M Sell
42,480
-6,953
-14% -$574K 0.1% 225
2024
Q4 		$4.25M Sell
49,433
-60,885
-55% -$6.58M 0.13% 165
2024
Q3 		$13.1M Buy
110,318
+10,187
+10% +$1.36M 0.39% 44
2024
Q2 		$14.3M Buy
100,131
+1,684
+2% +$223K 0.42% 36
2024
Q1 		$12.7M Buy
98,447
+3,913
+4% +$466K 0.4% 40
2023
Q4 		$9.78M Buy
94,534
+37,464
+66% +$3.7M 0.37% 55
2023
Q3 		$5.19M Sell
57,070
-19,956
-26% -$1.76M 0.22% 120
2023
Q2 		$6.23M Buy
77,026
+23,632
+44% +$1.93M 0.22% 112
2023
Q1 		$4.25M Sell
53,394
-3,198
-6% -$227K 0.17% 158
2022
Q4 		$3.83M Buy
56,592
+2,740
+5% +$161K 0.16% 158
2022
Q3 		$2.68M Sell
53,852
-107,328
-67% -$5.75M 0.12% 206
2022
Q2 		$8.98M Buy
161,180
+136,128
+543% +$7.55M 0.4% 41
2022
Q1 		$1.39M Buy
25,052
+13,994
+127% +$718K 0.06% 348
2021
Q4 		$619K Sell
11,058
-11,420
-51% -$619K 0.03% 416
2021
Q3 		$1.08M Buy
22,478
+2,232
+11% +$108K 0.05% 355
2021
Q2 		$848K Buy
20,246
+3,970
+24% +$154K 0.04% 413
2021
Q1 		$549K Buy
16,276
+6,610
+68% +$235K 0.03% 473
2020
Q4 		$338K Buy
+9,666
New +$334K 0.02% 508
2020
Q1 		– Sell
-12,684
Closed -$367K – 577
2019
Q4 		$367K Buy
+12,684
New +$351K 0.03% 451
2019
Q1 		– Sell
-14,744
Closed -$340K – 507
2018
Q4 		$340K Sell
14,744
-1,154
-7% -$25.6K 0.04% 358
2018
Q3 		$375K Buy
15,898
+2,880
+22% +$70.3K 0.04% 361
2018
Q2 		$300K Buy
13,018
+690
+6% +$16.4K 0.04% 365
2018
Q1 		$304K Buy
+12,328
New +$324K 0.04% 322

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Snowden Capital Advisors's NVO Position: Q2 2026 in Review

Snowden Capital Advisors increased its Novo Nordisk (NVO) stake by 1.9% in Q2 2026, buying an estimated $33.8K and bringing the position to 41,480 shares worth $1.99M. The position accounts for 0.05% of the portfolio, ranked #360.

Snowden Capital Advisors first reported a position in NVO in Q1 2018 and has held it in 28 quarters since. The position peaked at $14.3M in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Snowden Capital Advisors held 41,480 shares of Novo Nordisk worth $1.99M as of Q2 2026.
  • Snowden Capital Advisors bought 787 Novo Nordisk shares in Q2 2026, an estimated $33.8K.
  • Novo Nordisk made up 0.05% of Snowden Capital Advisors's portfolio in Q2 2026, its #360 holding.
  • Snowden Capital Advisors first reported a position in Novo Nordisk in Q1 2018 and has held it in 28 quarters since.
  • Snowden Capital Advisors's Novo Nordisk position peaked at $14.3M in Q2 2024.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.